Abstract

Serum adiponectin concentration is inversely associated with leptin and insulin concentration. There is little paucity of information in the literature on the adipocytes levels and regulations by resveratrol in cholesterol diet‐fed rabbit. Thirty rabbits were randomly divided into six groups, each of five animals: Group 1 = control, Group 2 = cholesterol diet (CD) only, Group 3 = resveratrol 200 mg/kg (R200), Group 4 = resveratrol 400 mg/kg (R400), Group 5 = CD + R200 and group 6 = CD + R400. The preparations were administered for eight weeks of experimental protocol. weight and blood glucose level were measured using digital weighing balance and glucometer on week zero and the eighth week of the experiment. At the end of the study period, the rabbits were placed under light anesthesia (ketamine) to remain unconscious. blood sample of about 3ml was drawn via cardiac puncture for serum extraction which were evaluated for serum concentration of metabolites assays (adiponectin, leptin and insulin). Blood glucose level and body weight were significantly higher in CD group compared to groups that received CD + resveratrol supplement and resveratrol only. Serum adiponectin showed significant (P < 0.05) increased in CD + resveratrol groups, compared to CD group only. Leptin and insulin significantly shows (P < 0.05) decreased in in CD groups co‐administered with resveratrol and resveratrol groups only compared to CD group only.in conclusion, the decrease in body weight and blood glucose level demonstrated the antidiabetic effect of resveratrol and increase in adiponectin level, decrease in leptin and insulin level following resveratrol supplement elucidated the therapeutic potential of resveratrol, despite cholesterol diet consumptions.Support or Funding InformationTETfUND (Tertiary Education Trust Fund Nigeria) and Ahmadu Bello University, Zaria, Kaduna State, NigeriaThis abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.